These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. McHutchison J, Sulkowski M. J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672 [Abstract] [Full Text] [Related]
26. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial. Mecenate F, Pellicelli AM, Barbaro G, Romano M, Barlattani A, Mazzoni E, Bonaventura ME, Nosotti L, Arcuri P, Picardi A, Barbarini G, D'Ambrosio C, Paffetti A, Andreoli A, Soccorsi F, Club Epatologi Ospedalieri (CLEO) Group. BMC Gastroenterol; 2010 Feb 19; 10():21. PubMed ID: 20170514 [Abstract] [Full Text] [Related]
30. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Mukherjee S, Lyden E. Hepatogastroenterology; 2006 Feb 19; 53(70):561-5. PubMed ID: 16995462 [Abstract] [Full Text] [Related]
32. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Lancet; 2014 Aug 02; 384(9941):414-26. PubMed ID: 24907224 [Abstract] [Full Text] [Related]
35. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients. Carosi G, Bruno R, Cariti G, Nasta P, Gulminetti R, Galli M, Angarano G, Verucchi G, Pontali E, Capetti A, Raise E, Ravasio V, Maida I, Iannacone C, Caputo A, Puoti M. Antivir Ther; 2014 Aug 02; 19(8):735-45. PubMed ID: 24583976 [Abstract] [Full Text] [Related]
36. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbreras C, Moreno E, Solís-Herruzo JA. Liver Transpl; 2006 Dec 02; 12(12):1805-12. PubMed ID: 17133585 [Abstract] [Full Text] [Related]
39. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, Garcia-Garzon S, Moreno A, Boullosa-Graña E, Rubio-Gonzalez EE, Garcia-Gonzalez M, Blesa C, Mateos ML. Am J Transplant; 2006 Oct 02; 6(10):2348-55. PubMed ID: 16869810 [Abstract] [Full Text] [Related]